(Q35091620)

English

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

0 references

Robert J. Heine

8

object named as

R J Heine

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

5

object named as

G Nijpels

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

J E Foley

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

M C Bunck

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

D L Möller-Goede

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

M Poelma

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

E M Eekhoff

6

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

A Schweizer

7

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

M Diamant

9

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

6 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

54

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1985-1991

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Clinical measures of islet function: usefulness to characterize defects in diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Five stages of evolving beta-cell dysfunction during progression to diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Glucose toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

8 July 2018

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

27 September 2018

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

27 September 2018

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

27 September 2018

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131517

27 September 2018

Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as “Isoglycemic” Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2167-8

21 January 2018

The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/21547496

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2167-8

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35091620&oldid=2197236154"